Sexually transmitted infections (STIs) constitute a major public health problem in the UK and may result in very costly complications. Many STIs pose the risk of a number of adverse pregnancy outcomes including miscarriage, still birth, preterm delivery, low birth weight and ophthalmia neonatorum. National guidelines for the management of STIs are produced and regularly revised by the British Association of Sexual Heath and HIV. This review outlines the latest recommended treatment options during pregnancy for the commonly encountered STIs.
Bacterial infections C. trachomatis
C. trachomatis is an obligate intracellular bacterium of which there are several serotypes. It is the most common bacterial STI in the UK, with the highest rates in patients under 25 years of age. Furthermore, results from the National Chlamydia Screening Programme demonstrated a high level of asymptomatic infection [101] . Complications in women include pelvic inflammatory disease, ectopic pregnancy and infertility. Chlamydia, like other acute bacterial and viral STIs, is associated with increased risk of both HIV transmission and acquisition [2] .
Untreated cervical chlamydia during pregnancy is associated with an increased risk of preterm delivery and premature rupture of membranes [3] . Mother-to-child transmission occurs at the time of vaginal birth and may result in ophthalmia neonatorum and pneumonitis in the infant and postpartum endometritis in the mother.
Nucleic acid amplification testing is the gold standard diagnostic method and offers high sensitivity (90-95%) and specificity. Endocervical or vaginal swabs are the specimens of choice and are of equivalent sensitivity.
Treatment of chlamydia during pregnancy
Erythromycin is safe for use in pregnancy but has a significant side-effect profile and is less efficacious (<95%) than azithromycin. The WHO recommends the use of azithromycin in pregnancy. The British National Formulary recommends the use of azithromycin in pregnant women only if no alternative is available, although the data that are available support its safety. When compared with erythromycin, meta-analysis showed amoxycillin to have a Sexually transmitted infections (STIs) constitute a major public health problem, not only in the UK but worldwide. A 2003 House of Commons Health Select Committee inquiry into sexual health described a sexual health crisis in the UK that amounted to a public health emergency [1] .
The number of newly diagnosed STIs in England remained high at 418,598 cases between 2008 and 2010 [101] . Many STIs pose the risk of a number of adverse pregnancy outcomes including miscarriage, still birth, preterm delivery, low birth weight and ophthalmia neonatorum. Effective management is imperative as STIs can be detrimental to both the mother and baby and can result in very costly complications.
Drugs selected for treatment should not be contraindicated in pregnant women, should have a high efficacy and be well tolerated.
The common STIs that are known to have significant implications in pregnancy are Chlamydia trachomatis, Neisseria gonorrhoeae, human papilloma virus (HPV), herpes simplex virus (HSV), Trichomonas vaginalis and syphilis. This review outlines the treatment options during pregnancy for the commonly encountered STIs. NICE has produced guidance for the routine antenatal care of healthy pregnant women, which includes specific recommendations for STI screening [102] . National guidelines for the management of STIs are produced and regularly revised by the British Association of Sexual Heath and HIV (BASHH) [103] . Readers are encouraged to review both NICE and BASHH guidelines for more comprehensive information.
It is beyond the remit of this article to discuss the management of HIV and hepatitis B during pregnancy.
Managing sexually transmitted infections in pregnant women similar cure rate and a better side-effect profile [4] . However, penicillin has been shown to induce chlamydial latency in vitro. Tetracyclines are contraindicated in pregnancy because of the risk of bone and dental abnormalities in the infant.
Recommended regimens for chlamydia during pregnancy can be found in Box 1.
Contact tracing of sexual partners must be pursued and patients should be advised to avoid any -including condom protected -sexual intercourse for at least 7 days after both the patient and their sexual partner(s) have completed treatment. A repeat swab for test of cure is recommended for all pregnant women 6 weeks after treatment [102] . It is the authors' practice to rescreen in the third trimester.
Gonorrhea
Gonorrhea is caused by the Gram-negative diplococcus N. gonorrhoeae. It is the second most common bacterial STI in the UK [101] . Up to 50% of women may be asymptomatic and may not present until complications such as pelvic inflammatory disease are present [5] . Gonorrhea is associated with serious sequelae such as infertility, ectopic pregnancy, chronic pelvic pain and disseminated gonococcal infection.
Preterm delivery, premature rupture of membranes, chorioamnionitis and postpartum infection are more common in pregnant women with untreated gonorrhea [6] . Gonorrhea is transmitted to the newborn from the mothers' genital tract during birth and can cause ophthalmia neonatorum and systemic neonatal infection.
Diagnosis is often made using nucleic acid amplification testing. These are highly sensitive tests (>96%) [7, 8] . Endocervical and vaginal swabs are of equivalent sensitivity [9] . False positives may occur, however. Confirmatory culture for gonococcus is essential to allow antimicrobial sensitivity testing, which is of paramount importance given increasing antibiotic resistance.
Treatment of gonorrhea during pregnancy
There is growing concern regarding the resistance and decreasing sensitivity of the gonococcus to many classes of antibiotics. Patients with gonorrhea frequently have concomitant infection with chlamydia. Intramuscular (im.) ceftriaxone plus cotreatment with azithromycin is now the first-line recommended treatment. Azithromycin is recommended as cotreatment irrespective of the results of chlamydia testing in order to prevent the emergence of cephalosporin resistance [10] . There is evidence to suggest synergy between azithromycin and cephalosporins [11] . Furthermore, pharyngeal gonorrhea may be more effectively eradicated with azithromycin cotreatment [12] .
Oral cefixime plus cotreatment with azithromycin is an alternative to im. ceftriaxone. In 2010, 6.3% of gonococcal isolates demonstrated decreased susceptibility to cefixime and in 2009, 0.3% to ceftriaxone [101] . A total of 35.7% of isolates were resistant to ciprofloxacin in 2010 [101] . Moreover, quinolones are contraindicated in pregnancy.
Recommended regimens for gonorrhea during pregnancy can be found in Box 2.
Partner notification must be pursued and patients are advised to abstain from sexual intercourse until they and their partners have been successfully treated. A test of cure is recommended 1 week after treatment in all cases in view of concerns regarding emerging resistance. It is the authors' practice to advise repeat screening in the third trimester.
Syphilis
Syphilis is caused by the spirochete Treponema pallidum. The incubation period of primary syphilis is 9-90 days. The primary ulcer (chancre) usually occurs at the site of inoculation, which is usually the genital or perianal area. The lesion is classically solitary and painless but can be multiple and painful. The primary chancre spontaneously resolves after a few weeks and may go unnoticed. Secondary syphilis develops 4-8 weeks later. It has a wide variety of presentations and may mimic many other diseases and may be easily misdiagnosed as glandular fever or another similar viral illness. Clinical features of secondary syphilis include rash, lymphadenopathy, mouth ulcers, fever and malaise. The symptoms and signs resolve without treatment. Long-term complications of untreated syphilis are neurological disease, cardiovascular disease and gummata (granulomatous skin lesions). There has been a marked increase in the number of cases of early syphilis observed since the late 1990s. There were a total of 2318 cases of early infectious syphilis diagnosed in England in 2010, albeit predominantly in men who have sex with men [101]. However, antepartum syphilis can have devastating consequences, resulting in preterm labor, polyhydramnios, hydrops, fetal death and congenital syphilis. Syphilis may be transmitted to the baby via the transplacental route at any stage of pregnancy.
In view of the potential profound adverse effects of syphilis during pregnancy it is recommended that all pregnant women in the UK are screened for syphilis at the initial antenatal appointment. Repeat serological testing may be indicated in women at high risk of syphilis, for example, those with sexual partners from high-risk groups or commercial sex workers.
Diagnosis and staging of disease is based on history, clinical examination and serology. Serology involves treponemal-specific tests and non treponemal tests. Treponemal-specific tests include treponemal enzyme immunoassay to detect IgG and IgM and T. pallidum particle agglutination. These tests are specific for T. pallidum and are reported as positive or negative.
The nontreponemal tests include the Venereal Disease Research Laboratory test and rapid plasma reagin. Nontreponemal test titers usually correlate with disease activity. False positives can occur in many conditions including pregnancy.
Treatment of syphilis during pregnancy
The clinical management of syphilis should be lead by a genitourinary medicine clinician. All patients diagnosed with syphilis should have their HIV test repeated. Treatment of syphilis in pregnancy should be with parenteral penicillin appropriate for the stage of syphilis. Pregnant women with early-stage syphilis and higher Venereal Disease Research Laboratory test result have a higher risk of having an infant with congenital syphilis after adequate treatment of maternal syphilis [13, 14] . Treatment in the last trimester is also associated with increased likelihood of congenital infection [13] [14] [15] [16] . Parenteral penicillin is the drug of choice as there are higher failure rates with nonpenicillin alternatives. Nonpenicillin alternatives include ceftriaxone, erythromycin and azithromycin. Penicillin desensitization should be considered in those patients reporting penicillin allergy [17] .
The Jarisch-Herxheimer reaction may occur just as for nonpregnant women. This may cause uterine contractions and fetal heart rate decelerations, which spontaneously resolve within 24 h. Steroids are not effective in reducing these effects and are usually only initiated 24 h prior to antibiotic therapy for cardiovascular syphilis, neurosyphilis or ophthalmological involvement in order to prevent complications arising from acute local inflammation.
Recommended regimens for syphilis during pregnancy can be found in Box 3. Partner notification is essential. Management should involve close liaison between genitourinary medicine, obstetrics and pediatrics. Both the mother and baby require close monitoring and follow-up.
Box 3. Recommended regimens for syphilis during pregnancy.

Early syphilis
Viral infections Genital herpes
Both HSV types 1 and 2 can cause genital herpes. Genital herpes is the most common ulcerative STI in the UK. The presence of genital ulcers also increases the likelihood of HIV transmission [18] .
Disease episodes may be first-episode or recurrent, and symptomatic or asymptomatic. First-episode genital herpes is subdivided into primary (newly acquired infection) and nonprimary infection (first clinical episode of a previously acquired herpes infection). It can be difficult to distinguish primary infection from the first clinically apparent episode of a previously acquired infection. Primary genital herpes can be very painful and distressing. Most clinicians make a clinical diagnosis and prescribe empirical treatment after taking swabs for HSV. Full STI and HIV screening is important, but swabs are usually deferred until the lesions have healed.
The diagnosis is confirmed by obtaining a swab from the base of an ulcer. HSV DNA detection by PCR is more sensitive than culture [19] . PCR can distinguish HSV-1 from HSV-2. Serology can be difficult to interpret and may not become positive for 6-8 weeks after a primary episode. Routine serology has poor specificity. Type-specific serology is expensive and type-1-seropositivity fails to differentiate between oropharyngeal and genital herpes infections.
The main risks of genital herpes during pregnancy are first or second trimester miscarriage and neonatal herpes. The highest risk of neonatal herpes is in women who acquire HSV during the third trimester. A prospective study of 58,000 women in the USA found 202 cases where HSV was isolated at the time of labor [20] . There were ten cases of neonatal herpes. Transmission is usually from direct contact with the virus during delivery; in utero transmission can occur but is rare. Untreated neonatal herpes is associated with a high mortality and can cause disability even with appropriate timely treatment.
Treatment of HSV in pregnancy
General advice includes saline bathing and analgesia. Management of genital herpes in pregnancy is determined by the gestation of the pregnancy at the time of herpes acquisition and can be categorized into management of first episodes and recurrent episodes. However, this can be difficult to distinguish clinically. Obtaining paired serum samples for type-specific serology several weeks apart may be useful to demonstrate seroconversion (i.e., recent infection).
First-episode genital herpes in first or second trimester
If first-episode genital herpes occurs in the first or second trimester, there is an association with miscarriage but there is no conclusive evidence that it causes birth defects. A 3-5 day course of aciclovir should be used to reduce the severity and duration of the episode. Although aciclovir is not licensed for use in pregnancy, it appears to be relatively safe [21] .
Prophylactic suppressive aciclovir from 36 weeks gestation may be considered in order to reduce the likelihood of a HSV outbreak at labor, ultimately reducing the likelihood of Cesarean section [22] .
In the absence of lesions or prodromal symptoms at labor, vaginal delivery should be anticipated.
First-episode genital herpes in third trimester
The risk of neonatal herpes is greatest when the mother acquires herpes in the third trimester. The mother acquires herpes but is unable to develop IgG antibodies before delivery and so the baby is born without the protection of passive immunity. In this situation, there is a 30-50% risk of neonatal herpes [22, 23] . Therefore, all women with first-episode genital herpes at the time of delivery or within 6 weeks of the expected date of delivery should be offered Cesarean section [102] . However, there are no published randomized controlled trials evaluating the effectiveness of Cesarean section for the prevention of neonatal herpes.
Recurrent genital herpes
Pregnant women who acquired HSV prior to pregnancy will already have IgG antibodies to HSV and will pass these antibodies to the fetus. Neonatal herpes is uncommon in this situation. If there are HSV lesions at the time of vaginal birth, the risk of neonatal herpes is reported to be 2-5% [24] . There is a small risk of asymptomatic shedding and the risk of neonatal herpes in these cases is reported to be 0.02-0.05% [24, 25] . Suppressive aciclovir should be considered from 36 weeks until delivery in order to prevent clinical recurrences and therefore reduce the need for Cesarean section [26] . Cesarean section should be considered if there are genital lesions at the onset of labor. Vaginal delivery should be anticipated if there are no lesions present at delivery. The risk of neonatal herpes following vaginal delivery is small and one must balance this against the risk of Cesarean section to the mother [24] .
Recommended regimens for HSV can be found in Box 4 (see text as above).
HPV
Genital warts are caused by infection with HPV and are the most prevalent viral STI diagnosed in the UK. Infection may not be clinically apparent.
There are over 100 documented HPV genotypes of which approximately 40 are tropic for anogenital skin. Most anogenital warts are benign; however, there are certain genotypes that are associated with an increased risk of anogenital neoplasia, specifically, genotypes 16 and 18 are associated with the greatest risk. External warts are generally due to types 6 and 11, which are not considered to be oncogenic. However, warts can also be caused by other oncogenic strains [27, 28] . The most important risk of HPV infection to women is the risk of anogenital cancer. The recent introduction of HPV vaccination programs has led to a significant decrease in high-grade smear abnormalities [29] . Quadrivalent HPV vaccination has also resulted in decreased incidence of genital warts [30] .
Genital warts may increase in size and number during pregnancy. The diagnosis is usually made clinically upon visual inspection. Maternal infection is associated with juvenile laryngeal papillomatosis in the infant. This is a rare condition that can cause hoarseness and respiratory distress in children. Cesarean section is not indicated in mothers with genital warts as vertical transmission of HPV is rare [31] .
Treatment of HPV during pregnancy
The same as in nonpregnant patients, treatment is usually for cosmetic rather than medical purposes in the majority of cases. Treatment is only really necessary in the unlikely event that the warts cause obstruction of the birth canal and impede vaginal delivery. All treatments have significant failure and relapse rates [32] and no single treatment is considered to be better than another. Cryotherapy with liquid nitrogen causes cytolysis at the dermo-epidermal junction and is safe for use in pregnancy.
A freeze/thaw technique should be employed, whereby liquid nitrogen is applied for approximately 10 s until a halo of freeze develops a few millimetres around the wart. This is repeated three or more times for each lesion during the treatment session. Cryotherapy can be administered every 1-2 weeks. Lesions may regress after delivery without any treatment. Podophyllin, podophyllotoxin and imiquimod should be avoided in pregnancy. Contact tracing is not required.
Protozoal infections T. vaginalis
T. vaginalis is a flagellated protozoan. Women may experience offensive discharge, dysuria and vulval irritation but may also be asymptomatic. Infection in pregnancy is associated with premature delivery and low birth weight [33, 34] . Neonatal infection is uncommon but should be considered in infants with vaginal discharge or unexplained respiratory disease. Nasal secretions, tracheal secretions, urine and vaginal swabs from the neonate should be closely examined for trichomonads [35] .
The diagnosis is confirmed by direct microscopy of a wet-mount preparation of vaginal secretions from the posterior fornix. This method of diagnosis is routinely employed in genitourinary medicine clinics. Microscopy has a sensitivity of approximately 70% [36] . Culture of vaginal secretions using specific media is more sensitive but rarely available now. Highly sensitive PCR techniques have been developed but are not yet in routine use.
Treatment of T. vaginalis during pregnancy
Metronidazole is the drug of choice and is highly efficacious. Metronidazole appears to be safe for use during the first trimester of pregnancy [37] . The British National Formulary advises avoiding high-dose metronidazole in pregnancy. Patients should be advised to abstain from alcohol while taking metronidazole and for 48 h afterwards because of possible disulfiram-like reaction.
Recommended regime for T. vaginalis can be found in Box 5. Patients should be advised to abstain from intercourse until they and their partner have been successfully treated. It is the authors' practice to perform a test of cure 1 week later in all cases.
Other
Bacterial vaginosis
Bacterial vaginosis is not regarded as an STI but its prevalence is higher in sexually active women. Bacterial vaginosis is a condition resulting from replacement of the usual H 2 O 2 lactobacilli in the vagina with anaerobic bacteria such as Mobiluncus sp. and Gardnerella vaginalis. It is a common cause of vaginal discharge in women of childbearing age but 50% of patients may be asymptomatic. A prevalence rate of 12% was found in pregnant women attending an antenatal clinic in the UK [38] . The patho physiology, particularly in the context of pregnancy, is poorly understood [39] . Bacterial vaginosis is associated with increased risk of preterm delivery, postpartum endometritis and pelvic inflammatory disease [40] .
The diagnosis can be confirmed using either clinical (Amsel's) criteria or Gram stain (Nugent or Hay-Ison) criteria. Amsel's criteria require at least three out of four of the following to be present: thin, white homogeneous discharge, clue cells on microscopy of wet mount, pH of vaginal fluid >4.5 or release of fishy odor upon adding alkali (10% potassium hydroxide) [41] . This so-called amine or 'whiff' test is not often performed in genitourinary medicine clinics now for health and safety reasons.
The Nugent score is determined by estimating the relative concentration of bacterial morphotypes that occur in bacterial vaginosis [42] . UK guidelines recommend using the Hay-Ison criteria:
• Grade 1/normal: Lactobacillus morphotypes predominate;
• Grade 2/intermediate: mixed flora with some lactobacilli present, but Gardnerella or Mobiluncus morphotypes also present;
• Grade 3/bacterial vaginosis: predominantly Gardnerella and/or Mobiluncus with few or absent lactobacilli [43] .
Treatment of bacterial vaginosis in pregnancy
Symptomatic women should be treated. However, the same as in nonpregnant women, asymptomatic pregnant women may opt for treatment if offered.
There are conflicting data regarding the value of screening and treating bacterial vaginosis in pregnancy. Evidence from systematic reviews does not support the routine screening and treatment of pregnant women with bacterial vaginosis [44] . However, other data suggest that screening and treating women at high risk for preterm delivery based on their history may significantly reduce the risk for preterm delivery [45] [46] [47] .
Metronidazole is the drug of choice and has an estimated cure rate of at least 70% [48] . Alcohol should be avoided during treatment and for 48 h after to prevent a disulfiram-like reaction.
Recommended regime for bacterial vaginosis in pregnancy can be found in Box 6.
Routine screening and treatment of male sexual partners is not required as studies have not shown any effect on likelihood of relapse [49] .
Conclusion
Many STIs pose the risk of a number of adverse pregnancy outcomes including miscarriage, still birth, preterm delivery, low birth weight and ophthalmia neonatorum. It should be emphasized that optimal management of any diagnosed STIs in pregnancy should include screening for other STIs and HIV, partner notification and follow-up where appropriate. Close liaison between genitourinary medicine, obstetrics and pediatrics is imperative. Patients should be given a detailed explanation of their condition with particular emphasis on the long-term health implications for themselves, their partners and the infant.
Early diagnosis and treatment of STIs not only alleviates symptoms and reduces complications, but also reduces the period of infectivity and onward transmission.
Future perspective
More emphasis needs to be placed on primary prevention of STIs with healthcare workers playing a key role in improving awareness and promoting sexual health. Increasing resistance to antibiotics, including third-generation cephalosporins, will make treatment for gonorrhea more challenging.
Current data regarding the value of screening for bacterial vaginosis in pregnancy is conflicting. More research is needed to identify if certain groups of pregnant women may benefit from screening and treatment of bacterial vaginosis.
Currently, only HIV, syphilis and hepatitis B are routinely screened for in UK antenatal clinics. Further work is needed to evaluate the outcomes of screening for other STIs known to have adverse effects in pregnancy.
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Executive summary
Background
• Sexually transmitted infections (STIs) constitute a major public health concern in the UK.
• STIs during pregnancy may be detrimental to both the mother and baby.
• Close liaison between genitourinary medicine, obstetrics and pediatrics is imperative.
• Effective management of an STI includes full screening for other STIs, a test of cure and partner notification where appropriate.
Bacterial infections • Chlamydia trachomatis
-Chlamydia is the most common bacterial STI in the UK with the highest rates among under 25-year-olds.
-Asymptomatic carriage is common.
-Although azithromycin is not licensed for use in pregnancy, there are data to support its safety for use in pregnancy. It is also recommended by the WHO as first-line treatment for chlamydia during pregnancy. 
Viral infections • Herpes simplex virus
-Risk of neonatal herpes is greatest when the mother acquires herpes simplex infection in the third trimester of pregnancy.
-Neonatal herpes is uncommon in women with known recurrent genital herpes.
-Data from the Aciclovir Pregnancy Registry support its safety for use in pregnant women. • Human papilloma virus -Warts may increase in size and number during pregnancy.
-Genital warts are usually treated for cosmetic reasons.
-It is unusual for warts to enlarge to the degree that would obstruct vaginal delivery.
-Cryotherapy with liquid nitrogen is safe for use in pregnancy.
-Recent introduction of a quadrivalent human papilloma virus vaccine has led to a falling incidence of high-grade cervical smear abnormalities and genital warts.
Protozoal infection
• Trichomonas vaginalis -Infection during pregnancy is associated with prematurity and low birth weight.
-Metronidazole is the drug of choice.
Other
• Bacterial vaginosis -Bacterial vaginosis is not regarded as an STI, however, it carries an increased risk of preterm delivery, postpartum endometritis and pelvic inflammatory disease. -Metronidazole is the drug of choice. -There are conflicting data regarding the value of screening and treating bacterial vaginosis in pregnancy. Current UK guidelines do not support the routine screening of pregnant women.
